Abstract
The efficacy of hydroxychloroquine (HCQ) in treating SARS-CoV-2 infection is harshly debated, with observational and intervention studies reporting contrasting results.
To clarify the role of HCQ in Covid-19 patients, we carried out a retrospective observational study of 4,396 unselected patients hospitalized for Covid-19 in Italy (February-May 2020). Patients’ characteristics were collected at entry, including age, sex, obesity, smoking status, blood parameters, history of diabetes, cancer, cardiovascular and chronic pulmonary diseases and medications in use. These were used to identify subtypes of patients with similar characteristics through hierarchical clustering based on Gower distance. Using multivariable Cox regressions, these clusters were then tested for association with mortality and modification of effect by treatment with HCQ.
We identified two clusters, one of 3,913 younger patients with lower circulating inflammation levels and better renal function, and one of 483 generally older and more comorbid subjects, more prevalently men and smokers. The latter group was at increased death risk adjusted by HCQ (HR[CI95%] = 3.80[3.08-4.67]), while HCQ showed an independent inverse association (0.51[0.43-0.61]), as well as a significant influence of cluster*HCQ interaction (p<0.001). This was driven by a differential association of HCQ with mortality between the high (0.89[0.65-1.22]) and the low risk cluster (0.46[0.39-0.54]). These effects survived adjustments for additional medications in use and were concordant with associations with disease severity and outcome.
These findings suggest a particularly beneficial effect of HCQ within low risk Covid-19 patients and may contribute clarifying the current controversy on HCQ efficacy in Covid-19 treatment.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors declare no competing financial interest. AG was supported by Fondazione Umberto Veronesi.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the institutional Ethical Committee of IRCCS Neuromed, Pozzilli, and of all recruiting centers (listed below). National Institute for Infectious Diseases L. Spallanzani, IRCCS, Rome Italy; University of Modena and Reggio Emilia, Modena, Italy; University of Pavia, Pavia. Italy; Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy; IRCCS Policlinico San Donato, San Donato Milanese. Italy; Maggiore della Carita Hospital, Novara, Italy; Humanitas Clinical and Research Hospital IRCCS, Rozzano-Milano, Italy; Azienda Sanitaria Locale (AUSL) di Pescara, Pescara, Italy; SS. Annunziata Hospital and University of Chieti, Chieti, Italy; Vita-Salute San Raffaele University, Milano, Italy; University of Insubria, Varese, Italy; AOU Policlinico G.Rodolico - San Marco, Catania, Italy; Centro Cardiologico Monzino IRCCS, Milano, Italy; Ospedale Morgagni-Pierantoni, Forli, Italy; Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy; Azienda Ospedaliera Universitaria Pisana, Pisa, Italy; Ospedale San Gerardo, ASST Monza, Italy; University of Milano-Bicocca, Milano, Italy; University of Milano, Milano, Italy; University of Naples, Federico II, Naples, Italy; University of Palermo, Palermo, Italy; Ospedale di Cremona, Cremona, Italy; Azienda Ospedaliera dei Colli, Ospedale Cotugno, Napoli, Italy; ASL Napoli3 Sud COVID HOSPITAL Boscotrecase (NA), Italy; Ospedale di Ravenna. AUSL della Romagna, Ravenna, Italy; University of Padova, Padova, Italy; PO S. Maria di Loreto Nuovo, ASL NA1 Centro, Napoli, Italy; Ospedale Regionale F. Miulli, Acquaviva delle Fonti (BA), Italy; P.O. San Giuseppe Moscati, Taranto, Italy; ASST Milano Nord - Ospedale Edoardo Bassini; Cinisello Balsamo, Italy; Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy; P.O. Santissima Trinita di Cagliari, Cagliari, Italy; University Hospital of Padova, Padova, Italy; Magna Graecia University, Catanzaro, Italy. All ethical committees approved the study.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Raw data analyzed in the present work may be made available under approval by each local center involved in the study, in a way which does not affect patients' privacy.
